GREENVILLE, S.C., June 15 /PRNewswire-FirstCall/ -- Signalife, Inc. has announced that its manuscript entitled "Evaluation of Novel ECG Signal Processing on Quantification of Transient Ischemia and Baseline Wander Suppression" was accepted as contributed paper by the IEEE Engineering in Medicine and Biology Society (EMBS). This paper will be presented at the 29th Annual International Conference (EMBC 2007) to be held in Lyon, France from August 23-26, 2007. The manuscript was authored by the Signalife R&D team and Mitchell W. Krucoff, MD, Professor of Medicine at Duke University Medical Center, Durham, North Carolina.
The Institute of Electrical and Electronics Engineers (IEEE) is the world's leading professional association for the advancement of technology. EMBS, an IEEE society, is the largest international society of Biomedical Engineers with approximately 8,000 members throughout the world. It focuses on the application of concepts and methods of the physical and engineering sciences in biology and medicine. The EMBC 2007 will offer an opportunity to gather researchers, educators, and developers from academic fields and industries worldwide to share their research results and exchange ideas from all areas of biomedical engineering. The conference technical program will spotlight industrial research and leadership in the areas of biomedical engineering, biological sciences, medical physics, healthcare technologies and informatics, and pharmaceuticals. The conference will be held in conjunction with the biennial Conference of the French Society of Biological and Medical Engineering (SFGBM).
Budimir S. Drakulic, PhD, Signalife CTO commented: "This conference provides a significant opportunity for Signalife to present results of Fidelity 100 tests to the world-wide audience of biomedical engineers. Our manuscript reports clinical data obtained during DIVA study together with the data obtained during objective evaluation of Fidelity 100. We have evaluated Fidelity 100 against modern electrocardiographs from leading industry manufacturers using a simulator and ECG waveforms obtained from the MIT-BIH ST Change Database and the European ST-T Database. We believe that this paper and presentation, along with other upcoming papers to be submitted to the Journal of Cardiology, will confirm significance of Fidelity 100 and its technology to the ECG community."
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.
Signalife, Inc.CONTACT: Kevin Kading of Signalife, Inc., +1-212-918-4606
Web site: http://www.Signalife.com/
